Jinseu Park, Duk-Soo Kim, Seung Hoon Sheen, Kwang-Gill Lee, Dong Hwa Heo, Seok Woo Kang, HaeYong Kweon, Dae Won Kim, Gyojun Hwang, Won Sik Eum, Soo Young Choi, Hyun Sook Hwang, You-Young Jo, Suk Hyung Kang, and Yong-Jun Cho
Sericultural and Agicultural Materials Division, National Academy of Agricultural Science, RDA, Suwon 441-100, KoreaReceived: November 10, 2011 / Revised: November 18, 2011 / Accepted: December 8, 2011Silk fibroin (SF) peptide has been traditionally used as atreatment for flatulence, spasms, and phlegm. In this study,we examined whether SF peptide enhanced the anti-inflammatory effect of PEP-1-FK506 binding protein(PEP-1-FK506BP) through comparing the anti-inflammatoryactivities of SF peptide and/or PEP-1-FK506BP. In thepresence or absence of SF peptide, transduction levels ofPEP-1-FK506BP into HaCaT cells and mice skin andanti-inflammatory activities of PEP-1-FK506BP wereidentified by Western blot and histological analyses. SFpeptide alone effectively reduced both mice ear edemaand the elevated levels of cyclooxygenase-2, interleukin-6and -1β, and tumor necrosis factor-α, showing similaranti-inflammatory effect to that of PEP-1-FK506BP.Furthermore, co-treatment with SF peptide and PEP-1-FK506BP exhibited more enhanced anti-inflammatoryeffects than the samples treated with SF peptides or PEP-1-FK506BP alone, suggesting the possibility that SFpeptide and PEP-1-FK506BP might interact with eachother. Moreover, the transduction data demonstrated thatSF peptide did not affect the transduction of PEP-1-FK506BP into HaCaT cells and mice skin, indicating thatthe improvement of anti-inflammatory effect of PEP-1-FK506BP was not caused by enhanced transduction ofPEP-1-FK506BP. Thus, these results suggest the possibilitythat co-treatment with SF peptide and PEP-1-FK506BP maybe exploited as a useful therapy for various inflammation-related diseases.Keywords: Inflammation, PEP-1-FK506BP, protein transduction,reactive oxygen species, silk fibroin peptide, TPADuring various cellular processes, reactive oxygen species(ROS), such as hydroxyl radicals, superoxide anion, andhydrogen peroxide, are generated and, consequently, can causelipid peroxidation, DNA damage, cell death, and variousdiseases, resulting in inflammation, cancer, Parkinson’s disease,and ischemia [1, 5, 19]. Treatment with lipopolysaccharides(LPS) or 12-O-tetradecanoylphorbol-13-actate (TPA), knownas inflammation inducers used in animal models [25, 30],can activate macrophages and secrete pro-inflammatorymediators, such as cyclooxygenase-2 (COX-2) and induciblenitric oxide synthase (iNOS), and pro-inflammatory cytokines,including interleukin-6 (IL-6), interleukin-1beta (IL-1β), andtumor necrosis factor-alpha (TNF-α). In addition, nuclearfactor-kappaB (NF- κB) and mitogen-activated protein kinase(MAPK) pathway are related to inflammatory responses[7, 8].FK506 binding proteins (FK506BPs) are members of animmunophilins family, which can bind immunosuppressivedrugs such as rapamycin and FK506, used in prevention ofgraft rejection following organ transplantation [2, 11, 21].In particular, FK506BP, a small peptide of 12 kDa, wasfirst associated with rapamycin. The resultant FK506BP-rapamycin complex binds to and then disrupts the formationof activated mammalian target of rapamycin complex 1(mTORC1), which can control protein synthesis, cellproliferation, and cell growth in response to nutrients andgrowth factors, leading to the suppression of proteinsynthesis and cell growth [4, 6, 16]. Furthermore, wepreviously reported that, through fusing FK506BP with a